Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0927 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
Denis Poddubnyy¹, Yihua Liu², William Barchuk³, Robin Besuyen⁴, René Galien⁵, Yuan Tian², Vlad Malkov² and Angie Hertz², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Galapagos NV, Romainvulle, France
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1361 • ACR Convergence 2021
Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Nicola Gullick³, Gkikas Katsifis⁴, Anna Kandyli⁵, Jan Brandt-Jrgens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Maher Aassi¹⁰, Barbara Schulz¹⁰, Effie Pournara¹⁰ and Piotr Jagiello¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷University hospital of Tours, Rheumatology department, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QQ, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated long-lasting efficacy and a favorable safety profile in patients (pts) with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) across Phase…
Abstract Number: 0159 • ACR Convergence 2021
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Xenofon Baraliakos¹, Valeria Rios Rodriguez², Murat Torgutalp², Anil Dilbaryan², Hildrun Haibel³, Maryna Verba⁴, Joachim Sieper³, Jürgen Braun¹, Martin Rudwaleit⁵ and Denis Poddubnyy⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage…
Abstract Number: 0386 • ACR Convergence 2021
Delay to Diagnosis in Axial Spondyloarthritis: The Gap Is Closing, but Persistent Association with Severe Disease
Maria McWalter¹, Conall MacGearailt¹, Sinead Maguire², Finbar (Barry) O'Shea² and Gillian Fitzgerald³, ¹Galway University Hospitals, Galway, Ireland, ²St James's Hospital, Dublin, Ireland, ³Galway University Hospital, Galway, Ireland
Background/Purpose: Diagnostic delay in axial spondyloarthritis (axSpA) presents a challenge in the management of the condition, despite increased awareness. Reducing the gap between symptom onset…
Abstract Number: 0902 • ACR Convergence 2021
Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
Walter Maksymowych¹, Ulrich Weber², Jonathan Chan³, Raj Carmona⁴, James Yeung⁵, Sibel Zehra Aydin⁶, Jodie Reis⁷, Liam Martin⁸, Ariel Masetto⁹, Olga Ziouzina⁸, Dianne Mosher⁸, Stephanie Keeling¹⁰, Sherry Rohekar¹¹, Rana Dadashova¹², Joel Paschke¹², Amanda Carapellucci¹² and Robert Lambert¹³, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ³University of British Columbia, Vancouver, BC, Canada, ⁴St. Joseph's Healthcare Hamilton, Mississauga, ON, Canada, ⁵James Yeung Rheumatology, Richmond, BC, Canada, ⁶University of Ottawa , Faculty of Medicine, Rheumatology, Ottawa, ON, Canada, ⁷Polmed Research Inc, Saskatoon, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹University of Western Ontario - London, London, ON, Canada, ¹²CARE Arthritis, Edmonton, AB, Canada, ¹³University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis and classification of axial spondyloarthritis (axSpA) relies considerably on imaging evidence of sacroiliitis which has led to the development of classification criteria which…
Abstract Number: 0928 • ACR Convergence 2021
Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Yuan Tian², Jingting Xu², William Barchuk³, René Galien⁴, Robin Besuyen⁵, Yihua Liu², Vlad Malkov² and Angie Hertz², ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos NV, Romainvulle, France, ⁵Galapagos BV, Leiden, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1691 • ACR Convergence 2021
Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Gerd Burmester¹, Stanley Cohen², Kevin Winthrop³, Peter Nash⁴, Andrea Rubbert-Roth⁵, Atul Deodhar³, Ori Elkayam⁶, Eduardo Mysler⁷, Yoshiya Tanaka⁸, Jianzhong Liu⁹, Ana Paula Lacerda⁹, Bosny Pierre-Louis⁹, Tim Shaw¹⁰ and Philip Mease¹¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Oregon Health & Science University, Portland, OR, ⁴Griffith University, Brisbane, Australia, ⁵Kantonspital St Gallen, St.Gallen, Switzerland, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
Abstract Number: 0357 • ACR Convergence 2021
Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…
Abstract Number: 0489 • ACR Convergence 2021
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Kofi Mensah¹, Rajula Gaur¹, Jamie Connarn¹, Michael Thomas¹, Liangang Liu¹, Stuart Mair², Francisco Ramírez-Valle¹ and Maria Palmisano¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Quotient Sciences, Nottingham, United Kingdom
Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…
Abstract Number: 0903 • ACR Convergence 2021
Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?
Walter Maksymowych¹, Ulrich Weber², Xenofon Baraliakos³, Pedro Machado⁴, Susanne Pedersen⁵, Joachim Sieper⁶, Stephanie Wichuk⁷, Denis Poddubnyy⁸, Martin Rudwaleit⁹, Désirée van der Heijde¹⁰, Robert Landewé¹¹, Joel Paschke¹², Mikkel Ostergaard¹³ and Robert Lambert⁷, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹²CARE Arthritis, Edmonton, AB, Canada, ¹³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: There is no international consensus on the optimal number of slices for evaluation of MRI structural lesions in the SIJ. An “all slice” method…
Abstract Number: 0930 • ACR Convergence 2021
Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Mikkel Ostergaard¹, Joseph Wu², Lara Fallon³, Sarah P Sherlock⁴, Cunshan Wang², Dona L Fleishaker², Keith S Kanik² and Walter Maksymowych⁵, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ²Pfizer Inc, Groton, CT, ³Pfizer Canada, Montréal, QC, Canada, ⁴Pfizer Inc, Cambridge, MA, ⁵Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: The Canada-Denmark (CANDEN) MRI scoring system enables detailed anatomy-based evaluation of inflammatory and structural lesions in spinal vertebral bodies and posterior elements in patients…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 0359 • ACR Convergence 2021
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Denis Poddubnyy², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, Sergio Sanz-Gomez⁷, Pedro Plazuelo-Ramos⁸ and Victoria Navarro-Compán⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
Abstract Number: 0491 • ACR Convergence 2021
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Lianne Gensler¹, Atul Deodhar², Désirée van der Heijde³, Denis Poddubnyy⁴, Alan Kivitz⁵, Maxime Dougados⁶, Natasha de Peyrecave⁷, Marga Oortgiesen⁸, Thomas Vaux⁹, Carmen Fleurinck⁷ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 0904 • ACR Convergence 2021
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Walter Maksymowych¹, Robert Lambert², Xenofon Baraliakos³, Susanne Pedersen⁴, Iris Eshed⁵, Ulrich Weber⁶, Pedro Machado⁷, Manouk de Hooge⁸, Joachim Sieper⁹, Stephanie Wichuk², Denis Poddubnyy¹⁰, Martin Rudwaleit¹¹, Robert Landewé¹², Désirée van der Heijde¹³ and Mikkel Ostergaard¹⁴, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁵Sheba Medical Center, Ramat Gan, Israel, ⁶Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: The ASAS definition of a positive MRI for inflammation in the spine (ASAS-MRI+) is intended for classification of patients as having axSpA but is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].